Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice-Reference-Cited by-同舟云学术

Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice

Published:2016-02 Issue:4 Volume:45 Page:386-390
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Narváez Javier,Magallares Berta,Díaz Torné César,Hernández Maria Victoria,Reina Delia,Corominas Héctor,Sanmartí Raimon,LLobet Josep Maria,Rodriguez de la Serna Arturo,Nolla Joan Miquel

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference26 articles.

1. Treating rheumatoid arthritis to target: recommendations of an international task force;Smolen;Ann Rheum Dis,2010

2. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement;Schoels;Ann Rheum Dis,2013

3. EMA. RoActemra (tocilizumab). Summary of product characteristics, 〈http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf〉; 2012 [accessed 15.03.12].

4. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis;Arnett;Arthritis Rheum,1988

5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study;Arthritis Research & Therapy;2024-07-12

2. Pharmacogenetics of therapies in rheumatoid arthritis: An update;Best Practice & Research Clinical Rheumatology;2024-07

3. Predictors of tumor necrosis factor inhibitors primary failure in rheumatoid arthritis patients;Egyptian Rheumatology and Rehabilitation;2024-05-30

4. Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis;Arthritis Research & Therapy;2023-11-24

5. Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort;Immunological Medicine;2023-01-23